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Introduction
Lung cancer is the most frequent cause of cancer death
in the USA, with a mortality of approximately 85%
for all stages, according to population statistics [1].
Furthermore, it is the most common cancer both in
incidence rate and in death rate in developing coun-
tries such as China [2]. Clinical data have shown that
most lung cancer patients eventually suffer relapse
and⁄or metastasis after complete excision of the
cancer, even if they were at stage IA [3]. Despite the
progress that has been made in recent decades,
the mechanism of lung cancer development, including
relapse and metastasis, is not fully understood.
Growth factor signal transduction pathways play
key roles in various physiological and pathological
processes, encompassing metabolism, growth, prolifer-
ation, stress, development, and apoptosis. Abnormali-
ties in these signaling pathways lead to various
developmental disorders and diseases. In severe cases,
aberrant growth factor signaling may even give rise to
tumors. Among these pathways, epidermal growth
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Both the epidermal growth factor receptor signaling pathway and micro-
RNA (miRNA) play an important role in lung cancer development and
progression. To address the potential role of miRNA in epidermal growth
factor receptor signaling, we identiﬁed miR-125a-5p as a downstream
target, using an miRNA array. We further demonstrated that miR-125a-5p
inhibited migration and invasion of lung cancer cells. Moreover, miR-125a-
5p regulated the expression of several downstream genes of epidermal
growth factor receptor signaling. Importantly, examination of lung cancer
samples revealed a signiﬁcant correlation of miR-125a-5p repression with
lung carcinogenesis. Taken together, our results provide compelling evi-
dence that miR-125a-5p, an epidermal growth factor-signaling-regulated
miRNA, may function as a metastatic suppressor.
Abbreviations
ECM, extracellular matrix; EGF, epidermal growth factor; EGRF, epidermal growth factor receptor; ERK, extracellular signal-related kinase;
FACS, ﬂuorescence-activated cell sorting; miRNA, microRNA; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide.
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ularly important for epithelial malignancies, including
lung cancer [4]. However, despite the clinical impor-
tance, the underlying molecular mechanism by which
EGFR signaling regulates lung cancer development
remains poorly understood.
Recent studies have indicated that microRNAs
(miRNAs) are extensively involved in various signaling
pathways [5–7]. MicroRNAs are a class of small, non-
coding RNAs that play important roles in different
biological processes. Interestingly, since Calin et al.
ﬁrst reported that miR-15 and miR-16 are deleted or
downregulated in the majority (approximately 68%) of
chronic lymphocytic leukemia cases [8], accumulating
evidence has implicated miRNA in human cancer [9].
Additionally, altered expression of miRNA has been
shown to mediate tumor metastasis [10,11]. However,
the relationship between miRNA and EGFR signaling
remains largely elusive.
Here, we set out to characterize the regulation of
miRNA expression by EGFR activation, using micro-
array analysis. We further determined that miR-125a-
5p could negatively regulate lung cancer cell migration
and invasion in vitro, and that this was frequently
decreased in lung cancer patients. Our data strongly
implicate miR-125a-5p as a potential inhibitor of
tumor metastasis.
Results
Repression of miR-125a-5p in response to EGFR
activation in lung cancer cells
It has been well established that EGFR signaling plays a
crucial role in lung tumorigenesis. Interestingly, accu-
mulating evidence has now implicated miRNA in the
formation and malignant progression of human cancer.
To examine the potential relationship between EGFR
signaling and miRNA, we ﬁrst performed miRNA exp-
ression proﬁling after epidermal growth factor (EGF)
stimulation using the miRHuman_10.0_070802 miRNA
array, which contains 711 probes. Through comparison
of RNA prepared from a combination of three lung
cells, A549, PC9, and H1299, before or after EGF stim-
ulation, our proﬁling analysis revealed 39 miRNAs with
signiﬁcantly different expression levels (P < 0.01;
Table 1). To further determine the requirement for
EGFR signaling in the expression of miRNA listed in
Table 1, we blocked EGFR signaling with geﬁtinib.
Geﬁtinib is an inhibitor of tyrosine kinase that competes
with ATP for binding to the intracellular kinase domain,
preventing receptor activation and the engagement of
downstream signaling transducers [12]. Thus, it has been
widely used to interfere with EGFR signaling. Consis-
tent with previous observations [13,14], PC9 cells, which
express a mutant EGFR and have been extensively
explored before, were more sensitive to geﬁtinib. Thus, a
low concentration of geﬁtinib could abolish the phos-
phorylation of EGFR, extracellular signal-related
kinase (ERK)1⁄2 and Akt after EGF stimulation. How-
ever, H1299 and A549 cells expressed wild-type EGFR,
and were less sensitive to geﬁtinib. Only a high concen-
tration of geﬁtinib could decrease the phosphorylation
of EGFR, ERK1⁄2, and Akt after EGF stimulation
(Fig. 1A). Accordingly, our miRNA array analysis
showed that, among the 39 miRNAs listed in Table 1,
Table 1. MicroRNA array analysis showed 39 miRNAs were in
response to EGF stimulation in lung cancer cells (P < 0.01).
Name Prestimulation Poststimulation Log ratio
miR-542-5p 51 228 3.19
miR-29b 169 506 1.57
miR-663 621 1125 1.16
let-7i 4494 8048 0.47
miR-25 5162 6490 0.43
miR-19b 909 1077 0.37
miR-29a 10 713 12 060 0.29
miR-15a 538 596 0.26
miR-24 9069 10 155 0.21
miR-17 6205 5218 )0.25
miR-106a 5990 4989 )0.28
miR-455-3p 303 263 )0.32
miR-151-5p 6483 5093 )0.34
miR-484 299 238 )0.35
miR-23a 21 099 17 298 )0.36
miR-181b 1309 1207 )0.41
miR-30d 1661 1203 )0.43
miR-26a 11 565 9160 )0.44
miR-361-5p 3379 2631 )0.44
miR-183 1536 1267 )0.51
miR-23b 21 710 15 380 )0.54
miR-15b 11 620 8384 )0.64
miR-130a 315 255 )0.64
miR-331-3p 272 164 )0.65
miR-99b 2920 1896 )0.69
let-7a 21 505 13 477 )0.80
miR-30c 5450 3314 )0.81
miR-224 2871 2090 )0.87
miR-30b 4382 2658 )0.92
let-7f 16 236 10 547 )0.94
miR-125a-5p 6882 3518 )1.03
let-7e 9822 5648 )1.06
let-7d 14 071 8423 )1.08
let-7c 13 905 7087 )1.21
miR-200c 7237 6774 )1.23
miR-574-5p 666 410 )1.28
miR-342-3p 394 174 )1.29
let-7b 7853 3379 )1.48
miR-122 5148 254 )3.54
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29b, and miR-125a-5p, could be reversed by geﬁtinib
(Fig. 1B).
We further veriﬁed our array results by quantitative
PCR, which revealed the expression of miR-24, miR-25,
miR-29b and miR-125a-5p to be bona ﬁde targets of
EGFR signaling (signiﬁcantly regulated by EGF treat-
ment and reversed by geﬁtinib). Among these candi-
dates, miR-125a-5p appeared to be particularly
intriguing, because its level was altered most signiﬁ-
cantly by EGF stimulation (Fig. 1C), and it has been
shown that miR-125a regulates the phosphorylation of
ERK1⁄2 and Akt in breast cancer cells [6].
MicroR-125a-5p negatively regulated cell
migration and invasion
EGFR signaling has been shown to play an important
role in cell migration and invasion [15]. Thus, the
marked repression of miR-125a-5p after EGFR activa-
tion prompted us to investigate whether miR-125a-5p
inﬂuenced tumor metastasis. We ﬁrst performed Tran-
swell cell migration assays. PC9 cells were selected as a
model system with which to assess the function of miR-
125a-5p, because they expressed endogenous miR-125a-
5p at a relatively high level before EGF stimulation
(Fig. 1C). Our results showed that treatment with anti-
sense miR-125a-5p could signiﬁcantly increase cell
motility (Fig. 2A). To examine their invasion capability,
cells transfected with antisense miR-125a-5p or negative
control were plated on top of a layer of extracellular
matrix (ECM) extracted from mouse sarcoma. Consis-
tent with the migration results, knockdown of miR125a-
5p signiﬁcantly promoted invasion (Fig. 2A). To further
determine the function of miR125a-5p in cell migration,
we tested the polarized migration of cells by a wound-
healing assay. As shown in Fig. 2B, PC9 cells transfect-
ed with antisense miR125a-5p healed the scratch wound
much faster than the negative control. Representative
photographs of migration, invasion and wound-healing
are shown in Fig. 2C. Taken together, our data pointed
to an important role of miR-125a-5p in regulating cell
migration and invasion, suggesting that it might regu-
late the metastasis of lung cancer.
Inhibition of miR-125a-5p increased cell survival
and tube formation
In addition to regulating migration and invasion,
EGFR signaling also inﬂuences proliferation, angiogen-
esis, apoptosis, and cell cycle progression [15]. After
ﬁnding that miR-125a-5p negatively regulated cell
migration and invasion, we went on to determine
whether miR-125a-5p had an impact on cell prolifera-
tion, angiogenesis, apoptosis, and cell cycle progression.
We ﬁrst examined its potential function in cell prolifera-
tion, which contributes heavily to tumor development.
A comparison with mock-transfected cells showed that
antisense miR-125a-5p signiﬁcantly enhanced PC9 cell
growth (Fig. 3A).
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Fig. 1. Geﬁtinib inhibited EGF-induced EGFR, ERK1⁄2 and Akt
phosphorylation and reversed EGF-stimulated miRNA expression in
lung cancer cells. (A) Western blot showed that, after EGF
(20 ngÆmL
)1) stimulation, phosphorylation of EGFR, ERK1⁄2 and
Akt occurred in PC9, A549 and H1299 lung cancer cells, and that
this could be almost completely abolished by geﬁtinib at different
concentrations. (B) After EGF stimulation, miRNA microarray analy-
sis revealed that the expression of 39 miRNAs was signiﬁcantly
altered (P < 0.01). Among these, ﬁve miRNAs, let-7i, miR-24, miR-
25, miR-29b, and miR-125a-5p, were further conﬁrmed as EGFR-
regulated miRNAs by geﬁtinib treatment. **P < 0.01 as compared
with the serum-starved medium group. (C) Quantitative RT-PCR
showed that the mir-125a-5p level was signiﬁcantly reduced after
EGF (20 ngÆmL
)1) stimulation in all three cell lines, and that this
effect was reversed by geﬁtinib. The value for miR-125a-5p in the
EGF group was set at 1, and the relative amounts of miR-125a-5p
in the other groups were plotted as fold induction.
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also involved in angiogenesis, we treated ECV304 cells,
showing signiﬁcant expression of endogenous miR-
125a-5p (data not shown), with antisense miR-125a-5p.
After culture, angiogenesis was assessed with tube
formation assays. Consistent with its potential tumor-
suppressing role, we found that knockdown of
miR-125a-5p signiﬁcantly enhanced the tube formation
efﬁciency of ECV304 cells (Fig. 3B,C).
Subsequently, we performed ﬂuorescence-activated
cell sorting (FACS)-based cell cycle proﬁling and
apoptosis analysis. However, miR-125a-5p antisense
did not inﬂuence apoptosis or the cell cycle of PC9
cells (data not shown). Taken together, our results
demonstrated that miR-125a-5p played an inhibitory
role in lung cancer metastasis.
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Fig. 2. Promotional effects of antisense miR-125a-5p on migra-
tion and invasion of PC9 cells. (A) Assay of migration and inva-
sion of antisense miR-125a-5p across 8 lm porous membranes
relative to negative control. (B) Conﬂuent cell monolayers were
wounded with a pipette tip. Wound closure was monitored by
microscopy at the indicated times. Data are given as closed
width⁄scratched width (%). (C) Representative photomicro-
graphs of migration, invasion and wound-healing in PC9 cells
were taken with a Nikon ECLIPSETS 100 microscope.
**P < 0.001 and *P < 0.005, as compared with the negative
control. Magniﬁcation: for migration and invasion, ·200; for
wound-healing, ·100.
*
0
20
40
60
80
100
120
140 A
B
C
Negative control 30 nm antisense
R
e
l
a
t
i
v
e
 
r
a
t
i
o
 
t
o
n
e
g
a
t
i
v
e
 
c
o
n
t
r
o
l
30 nm antisense Negative control
**
R
e
l
a
t
i
v
e
 
r
a
t
i
o
 
t
o
n
e
g
a
t
i
v
e
 
c
o
n
t
r
o
l
0
20
40
60
80
100
120
140
160
180
Negative control 30 nm antisense
Length of tube
Fig. 3. Antisense miR-125a-5p facilitated the growth of PC9 cells
and tube formation of ECV304 cells. (A) PC9 cells (5 · 10
3) cells
were plated on 96-well plates. Forty-eight hours later, MTT was
added to each well for 3 h at 37  C, and then replaced by dim-
ethylsulfoxide. Absorbance was read at 570 nmolÆL
)1. The data
are presented as percentage of growth relative to the negative
control. (B) ECV304 cells were cultured in a 12-well plate coated
with ECM gel. Photographs of tube formation were taken using
a Nikon ECLIPSETS 100 microscope (under ·200 magniﬁcation).
(C) Total tube length was measured with IMAGE ANALYSIS software.
**P < 0.001, and P < 0.005, as compared with the negative
control.
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human lung cancers
To gain further insights into the role of miR-125a-5p
in lung carcinogenesis and to examine the clinical rele-
vance of our ﬁndings, we investigated the expression
of miR-125a-5p in a panel of lung cancer patient
samples together with paired counterpart normal tis-
sues. With the criterion of a 2
)DDCt value change of no
less than 2 between the malignant and normal groups,
we found that 33.33% (5⁄15) of lung cancer samples
showed signiﬁcantly decreased expression of miR-125a-
5p by real-time RT-PCR. Thus, our results suggested
that downregulation of miR-125a-5p might contribute,
at least partially, to lung cancer development in human
patients.
Discussion
The EGFR signal transduction pathway regulates
essential cellular functions, and appears to play a cen-
tral role in the etiology and progression of numerous
epithelial malignancies, including lung cancer [4].
Moreover, the function of EGFR mutations in survival
of lung cancer patients and clinical respones to geﬁti-
nib has been reported [16,17]. Thus, the identiﬁcation
and characterization of potential factors that regulate
EGFR pathways are critical to our understanding of
lung cancer development and progression.
Emerging evidence has revealed the profound role of
various miRNAs in regulating cancer development. Dif-
ferent miRNAs have been implicated in the formation
of neoplasms, malignant progression, and metastasis.
To examine the potential miRNA targets of EGFR sig-
naling, we used the miRHuman_10.0_070802 miRNA
array, and identiﬁed miR-125a-5p as being regulated by
EGFR activation. To examine the cellular function of
miR-125a-5p, we employed comprehensive in vitro
approaches to establish the inhibitory role of miR-125a-
5p in cell proliferation, angiogenesis, cell motility, and
invasion. It is also of great interest and importance to
note that about one-third of the human lung cancer
samples that we examined revealed signiﬁcant downre-
gulation of miR-125a-5p expression. Consistent with
our ﬁndings, miR-125a-5p has also been reported to be
downregulated in breast cancer biopsy specimens
[18,19]. Further investigations will be performed to
determine whether miR-125a-5p expression is clinically
correlated with lung cancer metastasis. Interestingly, the
present results, which showed miR-125a-5p negatively
regulating cancer cell metastasis, are consistent with our
previous work, which suggested that miR-125a-5p is
negatively correlated with lung cancer metastasis [11].
Together, the ﬁndings presented here strongly suggest
that miR-125a-5p may function as a tumor suppressor.
Except for let-7i, miR-24, miR-25, miR-29b, and
miR-125a-5p, our miRNA array analysis also indicated
another 42 miRNAs with signiﬁcant differences by
comparing miRNA expression before and after geﬁti-
nib treatment (P < 0.01; Table S2). Interestingly,
among them, some miRNAs, such as miR-16, miR-143,
miR-200b, and miR-205, were shown to be involved in
human cancer [8,20,21].
In view of our ﬁndings here and the results of Scott
et al. [6], showing that miR-125a blocked ERK1⁄2 and
Akt signaling in breast cancer cells, we will determine
whether miR-125a-5p regulates the phosphorylation of
Akt and⁄or ERK1⁄2 in lung cancer cells, and whether
miR-125a-5p downregulates ErbB2 and ErbB3 in lung
cancer cells, because the present work only focused on
the functional analysis of miR-125-a-5p.
In conclusion, we identiﬁed miR-125a-5p, an
EGFR-regulated miRNA, as a potential tumor meta-
stasis suppressor. Our results further substantiated the
role of miRNA in tumorigenesis, and revealed the pos-
sibility of using miRNAs as potential therapeutic
targets to speciﬁcally suppress oncogenic signaling
pathways that go awry in human cancers.
Experimental procedures
Cells and cultures
The human lung cancer cell line A549 was obtained from
the American Type Culture Collection (Manassas, VA,
USA) and maintained in Ham’s F12K medium (Invitrogen,
Carlsbad, CA,USA) supplemented with 10% fetal bovine
serum (Shanghai Sangon Biological Engineering Techno-
logy and Services Co., Ltd, Shanghai, China). The human
lung cancer cell lines H1299 and PC-9 were obtained from
Zhejiang Cancer Hospital and grown in RPMI-1640 med-
ium (Invitrogen) supplemented with 10% fetal bovine
serum. Human umbilical vein endothelial cells (ECV-304)
were obtained from the China Center for Type Culture
Collection (Wuhan, China), and cultured in RPMI-1640
medium supplemented with 10% fetal bovine serum.
Drugs and chemicals
Recombinant human EGF was purchased from Invitrogen.
Geﬁtinib (AstraZeneca, Macclesﬁeld, UK) was a gift from
D. Chunfeng (Zhejiang Hospital, Hangzhou, China). A
250 mg geﬁtinib tablet was dissolved in 25 mL of dimethyl-
sulfoxide and stored at )20  C. Antibody against EGFR
and antibody against phospho-EGFR were purchased from
Cell Signaling Technology (Beverly, MA, USA). Antibodies
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icon International, Inc. (CA, USA). Antibody against Akt
was from BioVision, Inc. (CA, USA), and antibody against
phospho-Akt was from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA).
Western blot analysis
To examine the inﬂuence of geﬁtinib on phosphorylation of
proteins, conﬂuent tumor cells were pretreated with geﬁti-
nib at 0, 1, 2, 5 and 10 lm for 2 h before exposure to EGF
(20 ngÆmL
)1) for 30 min at 37  C. The cells were then
rinsed with ice-cold NaCl⁄Pi, and lysed in chilled lysis buf-
fer comprising 10 mm Tris⁄HCl (pH 7.4), 1% NP-40, 0.1%
deoxycholic acid, 0.1% SDS, 150 mm NaCl, 1 mm EDTA,
and 1% Protease Inhibitor Cocktail (Sigma, CA, USA).
Protein concentrations were measured using the Bio-Rad
protein assay (Bio-Rad Laboratories, San Jose, CA, USA),
according to the manufacturer’s instructions. Then, 30 lg
portions of cell lysates were subjected to SDS⁄PAGE and
transferred to Immobilon membranes (Millipore, Bedford,
MA, USA). After transfer, the blots were incubated with
blocking solution, probed with various antibodies, and
washed. Proteins were detected using goat anti-(rabbit
IgG) (MultiSciences Biotech Co., Ltd, Hangzhou, China).
b-Actin (Anti-beta-Actin Monoclonal Antibody; Multi-
Sciences Biotech Co., Ltd, Hangzhou, China) was used as a
positive control.
RNA isolation and miRNA microarray
On the day after subculturing, cells were cultured under dif-
ferent conditions for 48 h: serum-starved medium, serum-
starved medium plus EGF (20 ngÆmL
)1), and serum-starved
medium plus 1 lm (PC9) or 10 lm (A549 and H1299) geﬁti-
nib plus EGF (20 ngÆmL
)1). RNA was extracted with Trizol
reagent (Invitrogen) as the standard method. Separation,
quality control, labeling, hybridization and scanning of
small RNA were performed by LC Sciences (Houston, TX,
USA), using the miRHuman_10.0_070802 miRNA array
chip, based on Sanger miRBase Release 10.0. Preliminary
statistical analysis was performed by LC Sciences on raw
data normalized by the locally weighted scatterplot smooth-
ing (LOWESS) method on the background-subtracted data.
Then, in-depth data analysis was performed to identify
EGFR-regulated miRNA expression. MicroRNA with
P < 0.01 was considered as having a signiﬁcant difference.
Real-time quantitative RT-PCR
Reverse transcription reactions were carried out using
dNTP, Moloney murine leukemia virus reverse transcrip-
tase and RiboLock ribonuclease inhibitor (Applied Bio-
systems, Foster City, CA, USA). Real-time PCR was
performed on an ABI PRISM 7300 Sequence Detection
System (Applied Biosystems), using an SYBR Green I
Real-Time PCR kit (GenePharma, Shanghai, China) for
miR-24, miR-25, miR-29b, and miR-125a-5p, and TaqMan
Universal PCR Master Mix, No AmpErase UNG (Applied
Biosystems) for let-7i; 5s and RUN6B (Applied Biosystems)
were used as positive controls. The relative expression levels
of miRNAs in each sample were calculated and quantiﬁed
by using the 2
)DDCt method after normalization for expres-
sion of positive control. Primers for reverse transcription
and PCR are given in Table S1.
Cell migration and invasion assay
We performed the Transwell insert (24-well insert; pore
size, 8 lm; Corning, Inc., Corning, NY, USA) assay to
evaluate PC9 cell migration and invasion in vitro. In both
the migration assay and the invasion assay, an initial equi-
librium, obtained by adding 0.6 mL of RPMI-1640 with
10% fetal bovine serum to the multiple-well plate, was
employed to enhance cell attachment. For the invasion
assay, the inserts were coated with extracellular matrix gel
from Engelbreth–Holm–Swarm mouse sarcoma (Sigma,
Santa Clara, CA, USA). On the following day, 1 · 10
5 cells
suspended in 0.1 mL of fresh medium without fetal bovine
serum were added to the insert. Forty-eight hours after
seeding, the cells on the upper surface of the membrane
were removed using cotton buds. Cell monolayers on the
lower surface of the insert were ﬁxed and stained using
standard cytological techniques. Six visual ﬁeld of each
insert were randomly counted under a microscope (using
10 · 20 lenses).
Wound-healing experiment
Cells (1 · 010
6) were seeded on six-well plates. Upon con-
ﬂuence, the cell layer was scratched with a P-200 pipette tip
(Qiagen, Valencia, CA, USA) and then grown in normal
conditions after being washed with culture medium. Photo-
graphs of the wound adjacent to reference lines scraped on
the bottom of the plate were taken using a Nikon
ECLIPSE TS100 microscope (under ·100 magniﬁcation),
and the wound-healing was measured at 0, 6, 12, 24, 36
and 48 h, respectively. Sextuple assays were performed for
each experiment. Data were described as closed width⁄
scratched width (%, mean ± standard deviation).
Tube formation assay
ECV304 cells (1 · 10
5) were cultured in a 12-well plate
coated with 200 lL of ECM gel. Photographs of the tube
formation were taken using a Nikon ECLIPSETS 100
microscope (under ·200 magniﬁcation), and the length of
tube was quantiﬁed with image analysis software (devel-
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on the Internet at http://rsb.info.nih.gov/nih-image/). Each
experiment was repeated three times.
Cell proliferation assay
A Vybrant 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazo-
lium bromide (MTT) Cell Proliferation Assay Kit (Invitro-
gen) was used to estimate the effect of antisense miR-25a-5p
on the proliferation of PC9 cells. Cells were seeded at a
density of 5 · 10
3 cells per well in 96-well plates. After incu-
bation for 48 h, 20 lL of MTT solution (5 mgÆmL
)1 in
NaCl⁄Pi) was added to each well for 3 h at 37  C. Subse-
quently, culture medium with MTT was removed, and
formazan crystals were reabsorbed in 200 lL of dimethylsulf-
oxide (Shanghai Sangon Biological Engineering Technology
and Services Co., Ltd, Shanghai, China). Absorbance was
read at 570 nmolÆL
)1 using a Universal Microplate Spectro-
photometer (Bio-tek Instruments, Inc., Winooski, VT, USA).
Each experiment was performed in six replicate wells. Values
for control cells were considered as 100% viability.
Apoptosis analysis
PC9 cells were seeded in six-well plates (1 · 10
6 cells per
well). Seventy-two hours post-transfection, the cells were
harvested and stained with ﬂuorescein isothiocyanate-conju-
gated antibody against annexin V and propidium iodide,
using the annexin V–ﬂuorescein isothiocyanate apoptosis
detection kit (B. D. Biosciences Pharmingen, San Jose, CA,
USA). Stained cells were then quantiﬁed by FACSCalibur
ﬂow cytometry (Becton Dickinson, Sandy, UT, USA).
Cell cycle detection
PC9 cells were plated in six-well plates (1 · 10
6 cells per
well). Seventy-two hours post-transfection, the adherent
cells and the supernatants were collected and centrifuged at
500 g for 10 min. Cell pellets were washed with NaCl⁄Pi
containing BSA (Invitrogen), ﬁxed using 70% methanol,
and stored at )20  C. The ﬁxed cells were subsequently
washed twice with NaCl⁄Pi and stained with PI and RNase
A (B. D. Biosciences Pharmingen), and DNA content was
analyzed by ﬂow cytometry (Becton Dickinson).
Human lung cancer samples
Primary human lung cancers and paired noncancerous nor-
mal lung samples were obtained from 15 patients treated at
the Zhejiang Province Cancer Hospital, with documented
informed consent being obtained in each case. Samples
were frozen in liquid nitrogen and stored at )80  C until
use. RNA extraction and quantitative RT-PCR were
performed as above.
Transfection
Cells were transfected with the Pre-miRTM miRNA Pre-
cursor of miR-125a-5p (Ambion, Inc., Austin, TX, USA)
and Anti-miR miRNA Inhibitors of miR-125a-5p (Ambion)
at 30 nmolÆL
)1 ﬁnal concentration, using NeoFx (Ambion).
Efﬁciency of transfection was conﬁrmed by real-time RT-
PCR. CyTM3-labeled Pre-miRTM Negative Control#1
(Ambion) and Anti-miR Negative Control#1 (Ambion)
were used as negative controls.
Statistical methods
Differences between groups were compared using Pearson’s
chi-square test for qualitative variables and Student’s t-test
for continuous variables. P < 0.05 was considered to be
signiﬁcant.
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